Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Busy Month: Russia Looks To Localization, Technology Transfer To Spur Innovation (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

It’s only 2012, but Russia’s Pharma 2020 program hit new highs last month with novel deals from Abbott, J&J, Merck and Pfizer.

You may also be interested in...



Beyond Herceptin, Roche Readies Breast Cancer Successors, Braces For Biosimilars

Up-and-coming candidate T-DM1 shows an efficacy advantage in the Phase III EMILIA study, offers significantly better side effect profile and improved quality of life.

Merck Makes Hepatitis C A Priority

Merck highlighted its hepatitis C franchise at its recent R&D day with analysts and journalists.

Pfizer Joins Russia Land Rush, But Chooses To Partner Rather Than Build

WASHINGTON - In the latest announcement from Big Pharma about going local in Russia, Pfizer Inc. said June 29 that it had signed a memorandum of understanding with ChemRar High Tech Center, a Moscow incubator, to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC081579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel